GIP Research: Gastric Inhibitory Polypeptide as a Metabolic Hormone¶

Executive Summary¶

Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a 42-amino acid incretin hormone secreted by enteroendocrine K-cells in the proximal small intestine.

GIP acts through the GIP receptor (GIPR), a class B G protein-coupled receptor, to promote glucose-dependent insulin secretion and regulate lipid metabolism. Historically overshadowed by GLP-1 due to early reports suggesting diminished GIP insulinotropic activity in type 2 diabetes, GIP has undergone a renaissance in metabolic research.

Recent evidence demonstrates that pharmacological GIP receptor activation, particularly in combination with GLP-1 receptor agonism, produces substantial improvements in glycemic control and body weight reduction.

This article reviews the current understanding of GIP biology, signaling mechanisms, and its emerging role in multi-receptor therapeutic strategies.

Background¶

GIP was first identified by Brown and Dryburgh in the early 1970s as a gastrointestinal factor that inhibited gastric acid secretion—hence its original name, "gastric inhibitory polypeptide." However, subsequent research revealed that GIP's primary physiological role is as an incretin hormone that potentiates glucose-stimulated insulin secretion.

The peptide is encoded by the GIP gene and produced in enteroendocrine K-cells, which are most abundant in the duodenum and proximal jejunum.

GIP comprises 42 amino acids with a molecular weight of approximately 5.2 kDa and shares structural homology with other members of the secretin-glucagon peptide family including GLP-1, glucagon, and secretin. For many years, GIP research was hindered by a significant observation: the insulinotropic effect of GIP appeared to be substantially reduced in patients with type 2 diabetes, a phenomenon termed "GIP resistance." This observation led to the perception that GIP lacked therapeutic utility, and research attention shifted predominantly toward GLP-1.

However, this view began to change in the 2010s when studies demonstrated that the GIP insulinotropic response could be restored under improved glycemic conditions and that GIP receptor agonists could promote weight loss—contradicting earlier assumptions about GIP's role in energy balance.

Scientific Explanation¶

The GIP receptor is a class B G protein-coupled receptor expressed in pancreatic beta cells, adipose tissue, bone, the central nervous system, and the gastrointestinal tract. Upon GIP binding, the receptor predominantly couples to the Gαs signaling pathway, leading to adenylyl cyclase activation, cAMP production, and downstream PKA and EPAC signaling. In beta cells, this potentiates glucose-stimulated insulin secretion through mechanisms similar to GLP-1, including enhanced calcium influx and exocytosis. In adipose tissue, GIP receptor activation stimulates lipoprotein lipase activity, promotes fatty acid uptake and re-esterification, and inhibits lipolysis. These effects position GIP as an important regulator of postprandial lipid metabolism. GIP also stimulates glucagon secretion from pancreatic alpha cells—a notable distinction from GLP-1, which suppresses glucagon release. This property has important metabolic implications and has driven research into how combined GIP and GLP-1 receptor agonism can be optimally balanced.

Mechanism¶

The molecular mechanisms of GIP receptor signaling reveal both similarities and important differences compared to GLP-1 receptor signaling. At the cellular level, GIPR activation in beta cells engages the cAMP/PKA/EPAC cascade, leading to closure of K-ATP channels, membrane depolarization, voltage-gated calcium channel opening, and calcium-dependent insulin granule exocytosis. The glucose dependence of this effect ensures that insulin secretion occurs primarily under hyperglycemic conditions. In adipocytes, GIP signaling via PKA and downstream elements such as hormone-sensitive lipase (HSL) exerts nuanced control over lipid storage and mobilization. Chronic GIPR activation increases adipocyte lipid buffering capacity, which has been proposed to mitigate the adverse effects of lipid spillover into non-adipose tissues.

This "lipid partitioning" hypothesis suggests that GIP helps direct dietary fat toward appropriate storage depots, thereby reducing ectopic lipid accumulation in the liver, muscle, and pancreas—tissues where excess lipid contributes to insulin resistance and beta-cell dysfunction.

In the brain, GIPR signaling in the hypothalamus and hindbrain modulates food intake and energy expenditure, though the specific neural circuits involved are less well-characterized than those for GLP-1.

GIP also crosses the blood-brain barrier via a saturable transport system, suggesting potential central actions in addition to signaling through local GIPR expression.

Research Evidence¶

Early research by Brown and colleagues established the identity and basic properties of GIP. Subsequent work by Nauck and colleagues demonstrated that pharmacological doses of GIP could stimulate insulin secretion in healthy individuals, and identified the phenomenon of impaired GIP responsiveness in type 2 diabetes. This finding was confirmed across multiple laboratories and shaped the prevailing view of GIP as a less promising therapeutic target than GLP-1. A major shift occurred with the development and clinical testing of tirzepatide, a balanced GIP and GLP-1 receptor agonist. In the SURPASS clinical trial program, tirzepatide produced dose-dependent reductions in HbA1c and body weight that exceeded those achieved with GLP-1 receptor agonists alone. The SURMOUNT obesity trials further demonstrated tirzepatide's substantial weight loss efficacy, with mean reductions of up to 22.5% at the highest dose. These results prompted a reassessment of GIP's role in metabolic physiology. Subsequent preclinical studies using selective GIP receptor agonists and antagonists in animal models helped clarify that GIPR agonism contributes to tirzepatide's efficacy, rather than being neutral as had been hypothesized. Research by Samms and colleagues demonstrated that a long-acting GIP receptor agonist alone reduces body weight and improves glycemic control in diet-induced obese mice, and that GIPR agonism synergizes with GLP-1R agonism in a receptor-interdependent manner. Controlled human physiology studies have further refined the understanding of GIP action. Gasbjerg and colleagues conducted elegant clamp studies in healthy volunteers demonstrating that separate and combined infusions of GIP and GLP-1 produce distinct effects on insulin and glucagon secretion.

These studies showed that GIP stimulates glucagon secretion at low glucose concentrations while potentiating insulin secretion at high glucose—a glucose-dependent bimodal action that differs fundamentally from GLP-1's glucose-dependent monophasic insulin stimulation and glucagon suppression.

This differential glucagon regulation has important implications for the combined use of GIP and GLP-1 receptor agonists, as the net effect on glucose homeostasis depends on the balance between insulinotropic, glucagonotropic, and glucagon-suppressive activities at any given glucose concentration.

Current Understanding¶

The contemporary scientific perspective positions GIP as a nuanced and important regulator of whole-body metabolism. GIP physiology is now understood to encompass both insulinotropic and glucagonotropic actions, along with direct effects on adipose tissue lipid metabolism, bone remodeling, and central appetite regulation.

The apparent "GIP resistance" in type 2 diabetes is now recognized as a reversible phenomenon that can be overcome by pharmacological GIP receptor activation under improved metabolic conditions or through the use of receptor agonists with enhanced potency and pharmacokinetics.

A key insight from recent research is that GIP receptor agonism and GLP-1 receptor agonism exert complementary and synergistic metabolic effects.

GLP-1R agonism provides robust glucose-dependent insulin secretion and satiety, while GIPR agonism contributes additional insulinotropic activity, enhances lipid buffering, and may differentially regulate energy expenditure.

The optimal balance between GIP and GLP-1 activation appears to be a critical determinant of overall therapeutic efficacy, with the balanced 1:1 ratio in tirzepatide proving particularly effective.

Future Research¶

Several exciting frontiers in GIP research are actively being explored. First, the mechanisms underlying GIP-GLP-1 synergy at the cellular and molecular level remain incompletely understood and represent a priority for basic research.

Studies investigating GIPR-GLP-1R heterodimerization, intracellular signal integration, and emergent signaling properties of dual agonists are underway.

Second, GIP receptor antagonists are being investigated for their potential to produce weight loss through a complementary mechanism—blocking GIP action in adipose tissue may promote fat mobilization, and early clinical results with GIPR antagonists have been promising. Third, the role of GIP in bone metabolism, where it appears to stimulate bone formation and inhibit resorption, suggests potential applications in osteoporosis. Fourth, GIP's effects on the central nervous system—including neuroprotection, cognitive function, and reward circuitry—represent an emerging area of investigation.

Fifth, GIP-based multi-receptor agonists that incorporate glucagon, amylin, or other metabolic signals may further optimize efficacy for specific metabolic phenotypes.

Finally, tissue-specific GIPR knockout models are being employed to delineate the individual contributions of GIP signaling in beta cells, adipocytes, neurons, and bone cells to the overall metabolic phenotype. An important emerging area is the role of GIP in adipose tissue inflammation and immune function. Adipose tissue macrophages express GIP receptors, and GIP signaling has been shown to promote an anti-inflammatory (M2-like) macrophage phenotype in some studies, which could contribute to improved adipose tissue function and systemic metabolic health.

However, pro-inflammatory effects of GIPR activation have also been reported under certain conditions, suggesting that the immunomodulatory effects of GIP may be context-dependent—influenced by the metabolic milieu, the duration of GIPR activation, and the specific adipose depot examined.

Understanding these immunomodulatory effects and their tissue-specific regulation is a priority for future GIP research, as it may inform the therapeutic strategy for GIP-based agonists versus antagonists in different metabolic contexts.

GIP in Cardiovascular Physiology and Disease¶

The cardiovascular effects of GIP are an active and evolving area of research with important therapeutic implications. GIP receptors are expressed in the myocardium, vascular smooth muscle, and endothelium, suggesting direct cardiac and vascular actions of the hormone.

Preclinical studies in rodent models have demonstrated that GIP receptor agonists can reduce infarct size in models of myocardial ischemia-reperfusion injury, attenuate pressure overload-induced cardiac hypertrophy, and improve left ventricular function in models of heart failure.

These cardioprotective effects appear to be mediated through cAMP/PKA-dependent signaling, enhanced nitric oxide production in the coronary endothelium, and modulation of cardiac fatty acid metabolism. The effect of GIP on cardiac metabolism is particularly relevant given the energetic demands of the failing heart.

GIP receptor activation has been shown to increase myocardial glucose uptake and glycolysis while maintaining fatty acid oxidation, an effect that may be beneficial in the context of the metabolic inflexibility characteristic of the failing heart.

Data from chronic GIP receptor agonist administration in diabetic mouse models has shown improved cardiac energetics, reduced fibrosis, and preserved systolic and diastolic function compared to vehicle-treated controls.

The contribution of GIPR activation to the cardiovascular benefits observed with tirzepatide in ongoing outcome trials is a subject of active investigation and may provide mechanistic insights that distinguish dual from single incretin receptor agonists in terms of cardioprotection. In the vasculature, GIP has been shown to modulate endothelial function and vascular tone. GIP induces nitric oxide-dependent vasodilation in isolated mesenteric arteries and in the coronary microvasculature.

Direct anti-atherosclerotic effects have been reported in some animal models, with GIPR agonists reducing macrophage foam cell formation and plaque area in ApoE knockout mice fed a Western diet.

However, pro-inflammatory effects of GIPR activation have also been described under certain conditions, suggesting that the vascular effects of GIP may be context-dependent.

These divergent findings underscore the need for further mechanistic studies and the importance of large-scale cardiovascular outcome trials to definitively establish the cardiovascular safety and benefit profile of GIP-based therapies.

Frequently Asked Questions¶

What is GIP and how does it differ from GLP-1?

GIP (gastric inhibitory polypeptide) is a 42-amino acid incretin hormone secreted by K-cells in the proximal small intestine. While both GIP and GLP-1 stimulate glucose-dependent insulin secretion, GIP also promotes glucagon secretion, regulates lipid metabolism in adipose tissue, and has distinct effects on bone remodeling.

Why was GIP considered less promising than GLP-1 for many years?

Early studies demonstrated that the insulinotropic effect of GIP is substantially reduced in patients with type 2 diabetes—a phenomenon termed "GIP resistance." This led to the assumption that GIP had limited therapeutic utility, while GLP-1 retained its insulinotropic activity in type 2 diabetes.

What is GIP resistance and can it be overcome?

GIP resistance refers to the diminished insulinotropic response to GIP observed in patients with type 2 diabetes. Importantly, this resistance can be partially reversed by achieving better glycemic control, and pharmacological doses of GIP receptor agonists with optimized pharmacokinetics can overcome the resistance to produce meaningful insulin secretion.

How does GIP affect lipid metabolism?

GIP promotes postprandial lipid storage by stimulating lipoprotein lipase activity, enhancing fatty acid uptake into adipocytes, and inhibiting lipolysis. This "lipid partitioning" effect helps direct dietary fat toward appropriate adipose storage depots and away from ectopic tissues.

Does GIP increase or decrease glucagon secretion?

GIP stimulates glucagon secretion from pancreatic alpha cells under euglycemic and hypoglycemic conditions, whereas GLP-1 suppresses glucagon. This difference is important for understanding the distinct pharmacology of GIP-based therapeutics.

What role does GIP play in bone health?

GIP receptors are expressed on osteoblasts and osteoclasts. GIP signaling promotes bone formation and inhibits bone resorption, suggesting potential anabolic effects on bone. This may have relevance for osteoporosis research and metabolic bone disease.

How does tirzepatide combine GIP and GLP-1 activity?

Tirzepatide is a single peptide molecule engineered to act as a dual agonist at both the GIP and GLP-1 receptors, with roughly balanced potency at both targets. This dual activity produces synergistic metabolic effects exceeding those of GLP-1R agonists alone, as demonstrated in the SURPASS and SURMOUNT clinical trial programs.

Is the GIP receptor expressed in the brain?

Yes, GIP receptors are expressed in the hypothalamus, hippocampus, and other brain regions. GIP can cross the blood-brain barrier via saturable transport, and central GIPR signaling modulates food intake, energy expenditure, and potentially cognitive function.

Could GIP antagonists be useful for weight loss?

Preclinical and early clinical evidence suggests that GIP receptor antagonists may promote weight loss through a different mechanism—reducing GIP-mediated lipid storage in adipose tissue. This represents a complementary approach to GIP receptor agonism and is an active area of investigation.

What are the main open questions in GIP research?

Key open questions include the precise mechanisms of GIP-GLP-1 synergy at the cellular level, the relative contributions of different GIP-responsive tissues to overall metabolic effects, the optimal GIP-to-GLP-1 activation ratio for different therapeutic goals, and the long-term effects of sustained GIPR modulation.

About RPL Peptides: RPL Peptides is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptides Data Center.

References¶

Gastroenterology

Diabetes, Obesity and Metabolism

Canadian Journal of Biochemistry

Cell Metabolism

Molecular Metabolism

Nature Communications

Nature Reviews Drug Discovery

New England Journal of Medicine

Endocrinology

Journal of Diabetes Investigation

Diabetes

— Written by the RPL Scientific Editorial Team | Last updated June 2025